Shares of GSK Pharma settled 2.38 per cent lower at Rs 1,479.60 apiece on the BSEGlaxoSmithKline (GSK) Pharmaceuticals reported a net revenue of Rs 14.33 crore on the consolidated basis in the January-March quarter for the financial year 2020-21.
According to a regulatory filing by the company to the stock market, GSK Pharmaceuticals reported a net revenue of Rs 138.07 in the corresponding quarter of the previous fiscal, marking a 90 percent year-on-year decrease in earnings during the fourth quarter of financial 2020-21.
According to the statement, GSK Pharmaceuticals earnings from operations during the March quarter stood at Rs 813.75 crore, compared to Rs 775.80 crore in the year-ago duration.
The business's profits from operations increased 5 per cent on a yearly basis during the January-March quarter.On Wednesday, May 19, GSK Pharmaceuticals' board of directors advised a final dividend of Rs 30 equity share of face value of Rs 10 each for the fiscal year 2020-21.
The company added that if the dividend is authorized by the members, then it will be paid on or after July 27, 2021.
Our recognized portfolio made gains in their market share in particular classifications, especially in the anti-infectives and pain restorative areas which have actually been important in the fight versus COVID.
We likewise continued to preserve our leadership in dermatology.
This development has even more enhanced our willpower to ensure clients get access to our medicines and vaccines that can make that lifesaving distinction, stated Sridhar Venkatesh, ManagingDirector, GlaxoSmithKline Pharmaceuticals Limited.On Wednesday, shares of GlaxoSmithKline Pharmaceuticals settled 2.38 percent lower at Rs 1,479.60 apiece on the BSE.
GSK Pharmaceuticals opened on the BSE at Rs 1,515.75, swinging to an intra day high of Rs 1,515.75 and an intra day low of Rs 1,456 throughout the session today.